Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNxt SolutionsXTER:BXT -9.27%31 PEG Ratio is 0.00 as of Aug. 13, 2026. GuruFocus rates XTER:BXT with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 346 Drug Manufacturers companies, BioNxt Solutions ranks worse than 289017.05% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for BioNxt Solutions's PEG Ratio or its related term are showing as below:
XTER:BXT's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.79 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
BioNxt Solutions PEG Ratio Related Terms
BioNxt Solutions PEG Ratio Historical Data
* Premium members only.
The historical data trend for BioNxt Solutions's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNxt Solutions PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's PEG Ratio distribution charts can be found below:
* The bar in red indicates where BioNxt Solutions's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
BioNxt Solutions (XTER:BXT) has a PEG Ratio of 0.00 as of Aug. 13, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on BioNxt Solutions and its competitors. According to the industry distribution chart, BioNxt Solutions ranks #999999 out of 346 companies in the Drug Manufacturers industry.
Is BioNxt Solutions' PEG Ratio too high?
BioNxt Solutions' current PEG Ratio is 0.00. Based on the distribution chart, BioNxt Solutions ranks #999999 out of 346 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioNxt Solutions has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioNxt Solutions ranks #999999 out of 346 companies for PEG Ratio. This places BioNxt Solutions in the lower half of its industry. The industry median PEG Ratio is 1.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.79, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on BioNxt Solutions and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNxt Solutions's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
BioNxt Solutions (XTER:BXT) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. BioNxt Solutions' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For BioNxt Solutions (XTER:BXT), the current PEG Ratio is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
31GF Score
Get the complete analysis for XTER:BXT
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:BXT has been successfully added to your 
